University of Illinois Chicago researchers have identified the ion channel protein KCNMB1 as a molecular switch that regulates cancer cell stiffness. By modulating this protein, scientists can harden soft, metastatic cancer cells, making them more vulnerable to destruction by the immune system, according to a study published in Developmental Cell.
The Physics of Metastasis
Cancer cells often evade the immune system by becoming physically soft and flexible, a trait that allows them to disseminate through the body. While a tumor’s outer shell may feel rigid, the individual cells within it are often “gooey,” said Ekrem Emrah Er, assistant professor of physiology and biophysics at the University of Illinois Chicago and senior author of the study. This flexibility allows them to resist the mechanical stress of immune cell attacks, causing T cells and natural killer cells to bounce off them like jelly rather than shattering the cancer cell.
Did you know?
Metastatic cancer cells use their soft nature to navigate the body’s circulatory system. This physical transformation is a key reason why they are harder for the immune system to eliminate compared to healthy, more rigid cells.
Targeting KCNMB1 to Restore Immune Recognition
The research team identified the potassium ion channel KCNMB1 as a critical downstream player in cellular stiffness. By increasing the activity of this channel, the researchers successfully increased the stiffness of cancerous cells in lab models. This shift rendered the cells significantly more susceptible to immune-mediated destruction.
Alexa Gajda, the study’s first author and a postdoctoral fellow at UIC, noted that targeting ion channels is a promising therapeutic strategy. Unlike previous targets such as the transcription factor MRTFA—which can trigger unintended downstream effects—ion channels are already well-understood targets in clinical medicine. Drugs that modulate these channels are currently used to manage conditions like cardiovascular disease and stroke.
Clinical Potential for Metastatic Cancer
In animal models of metastatic breast cancer, the team tested the potassium-channel activator BMS-204352. The drug effectively reduced the growth of tumors in the lungs by restoring the immune system’s ability to recognize and kill metastatic cells. According to the study, the treatment’s success relied on the presence of functional T cells, highlighting the importance of the immune system in this biophysical approach to cancer treatment.
The researchers also observed that tumors often create potassium-rich microenvironments that suppress immune responses by softening cancer cells. Activating KCNMB1 effectively reversed these local conditions, restoring cellular stiffness and enabling immune cells to mount a more effective response.
Frequently Asked Questions
What is the role of KCNMB1 in cancer?
KCNMB1 is an ion channel protein that regulates potassium movement across cell membranes. It acts as a switch for cell stiffness; when activated, it makes cancer cells stiffer and more vulnerable to immune system attacks.
Why are soft cancer cells harder to treat?
Soft cancer cells are flexible, allowing them to bend under the pressure of an immune cell attack rather than breaking. This makes them difficult for T cells and natural killer cells to destroy.
Is there a drug currently available for this?
The researchers tested the drug BMS-204352 in animal models. While the results are promising, the approach requires further research and clinical trials before it can be used in human patients.
Are you interested in the latest developments in oncology and biophysics? Subscribe to our newsletter for monthly updates on breakthroughs in cancer research. Have questions about this study? Leave a comment below.
Worth a look